Can a broader HPV vaccine boost protection after the original shot?

NCT ID NCT07530679

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test if giving a 9-valent HPV vaccine to women who previously received the bivalent HPV vaccine is safe and boosts their immune response. Researchers will enroll 360 healthy women aged 18-45 and compare two different dosing schedules (two doses vs. three doses) against a standard three-dose schedule in women not previously vaccinated. The goal is to see if the broader vaccine can provide additional protection against more HPV types.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
9-valent human papillomavirus vaccine
What this could lead to
If successful, this could show that a single booster or two-dose schedule of the 9-valent HPV vaccine is safe and effective for women already vaccinated with the bivalent vaccine, potentially simplifying future vaccination programs.
What could go wrong
This is an early-stage, open-label study with only 360 participants, so results may not apply to everyone. The study is not yet recruiting, and the immune response measured may not directly translate to long-term cancer prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.